Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does metergoline selectively attenuate 5-HT mediated prolactin release?

P M Ellis1, S E Gartside, C J Ware

  • 1MRC Unit of Clinical Pharmacology, Littlemore Hospital, Oxford, UK.

Psychopharmacology
|January 1, 1991
PubMed
Summary

Metergoline blocks prolactin release in humans, but not in rats, when given with a dopamine antagonist. This suggests serotonin mechanisms are not involved in human prolactin regulation by metergoline.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.

Investigational new drugs·2020
Same author

No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review.

Acta psychiatrica Scandinavica·2020
Same author

An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.

Current oncology (Toronto, Ont.)·2019
Same author

Resource use in the last three months of life by lung cancer patients in southern Ontario.

Current oncology (Toronto, Ont.)·2019
Same author

Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.

Current oncology (Toronto, Ont.)·2019

Area of Science:

  • Neuroendocrinology
  • Pharmacology
  • Serotonin and Dopamine Signaling

Background:

  • The non-selective 5-HT receptor antagonist metergoline affects prolactin release.
  • Previous studies suggest a role for serotonin (5-HT) in regulating prolactin secretion.
  • Understanding the mechanisms of prolactin regulation is crucial for various physiological and pathological conditions.

Purpose of the Study:

  • To investigate the role of serotonin (5-HT) in mediating prolactin release in response to dopamine receptor blockade in humans.
  • To compare the effects of metergoline on prolactin response in rats and humans.

Main Methods:

  • Male rats were administered metergoline (5-HT antagonist) followed by d-fenfluramine (5-HT releasing agent) or haloperidol (dopamine antagonist).
  • Healthy male volunteers received oral metergoline followed by intravenous haloperidol.

Related Experiment Videos

  • Prolactin levels were measured in both animal and human studies to assess the drug effects.

    • Main Results:

    • In rats, metergoline attenuated the prolactin response to d-fenfluramine but not to haloperidol.
    • In humans, oral metergoline completely blocked the prolactin response to intravenous haloperidol.
    • These contrasting results highlight species-specific differences in the mechanisms of prolactin regulation.

    Conclusions:

    • In humans, blockade of prolactin response by metergoline during dopamine receptor antagonism does not necessarily indicate 5-HT involvement.
    • The findings suggest that serotonin-mediated mechanisms are not the primary pathway for metergoline's effect on prolactin in humans under these conditions.
    • Further research is needed to elucidate the precise mechanisms of metergoline's action on prolactin secretion in humans.